The feasibility and safety of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results
Recommended Citation
Lee RJ, Hinson A, Bauernschmitt R, Matschke K, Fang Q, Mann DL, Dowling R, Schiller N, Sabbah HN. The feasibility and safety of Algisyl-LVR as a method of left ventricular augmentation in patients with dilated cardiomyopathy: Initial first in man clinical results. Int J Cardiol. Jul 2 2015;199:18-24.
Document Type
Article
Publication Date
11-15-2015
Publication Title
International journal of cardiology
Abstract
BACKGROUND: A tissue engineering approach to augment the left ventricular wall has been suggested as a means to treat patients with advanced heart failure. This study evaluated the safety and feasibility of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy undergoing open-heart surgery.
METHODS AND RESULTS: Eleven male patients (aged 44 to 74years) with advanced heart failure (NYHA class 3 or 4), a left ventricular ejection fraction (LVEF) of
CONCLUSIONS: Administration of Algisyl-LVR to patients with advanced HF at the time of cardiac surgery is feasible and safe; warranting continued development of Algisyl-LVR as a potential therapy in patients with advanced HF.
Medical Subject Headings
Adolescent; Adult; Aged; Alginates; Cardiac Surgical Procedures; Cardiomyopathy, Dilated; Echocardiography; Electrocardiography, Ambulatory; Feasibility Studies; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Injections; Male; Middle Aged; Stroke Volume; Time Factors; Tissue Engineering; Treatment Outcome; Ventricular Function, Left; Young Adult
PubMed ID
26173169
Volume
199
First Page
18
Last Page
24
